Board Member
Grace Therapeutics, Inc. (GRCE)Equibles does not estimate personal net worth.
Get an email with a short summary when Grace Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get GRCE alertsPrashant Kohli is recorded as Board Member at Grace Therapeutics, Inc. (GRCE) since September 30, 2024 and CEO at Grace Therapeutics, Inc. (GRCE). The newest filing on record that lists Prashant Kohli as CEO at Grace Therapeutics, Inc. (GRCE) is dated July 28, 2026. Grace Therapeutics, Inc. reported in an 8-K filed September 30, 2024 that Prashant Kohli was appointed director, effective September 30, 2024. Grace Therapeutics, Inc. reported in an 8-K filed April 5, 2023 that Prashant Kohli was appointed Chief Executive Officer, effective April 4, 2023. The proxy statement of Grace Therapeutics, Inc. reports total compensation of $1,270,820 for Prashant Kohli in fiscal 2026, including a base salary of $579,000. Disclosed compensation is on record for 3 fiscal years. Prashant Kohli has spoken on 1 investor event across 1 company, most recently for Grace Therapeutics, Inc. on September 17, 2026. Grace Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Grace Therapeutics, Inc. includes Robert J. DelAversano (CFO and Chief Accounting Officer), A. Brian Davis (Board Member), Donald Olds (Board Member) and 7 others.
“The following nominees were elected as directors by the votes indicated to serve until the close of the Company’s next annual meeting of shareholders or until his successor is elected or appointed: | Nominee | Votes For | Withheld | Broker Non-Votes | | --- | --- | --- | --- | | Vimal Kavuru | 5,883,771 | 71,334 | 1,194,221 | | A. Brian Davis | 5,902,562 | 52,543 | 1,194,221 | | S. George Kottayil | 5,902,813 | 52,292 | 1,194,221 | | Prashant Kohli | 5,902,397 | 52,708 | 1,194,221 |”
“On April 4, 2023, Acasti Pharma Inc. (the "Company") announced it has appointed Prashant Kohli as the Company's Chief Executive Officer, succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.”
“I now ask that Mr. Coley report on the existence of a quorum.”
2024-09-30–present
Start not stated–present
Last confirmed July 28, 2026
Biotechnology · Healthcare
CEO, Board Member
2024-09-30–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2026 | Grace Therapeutics, Inc. (GRCE) | Chief Executive Officer | $579,000 | $1,270,820 |
| 2025 | Grace Therapeutics, Inc. (GRCE) | Chief Executive Officer | $500,000 | $1,074,621 |
| 2024 | Grace Therapeutics, Inc. (GRCE) | Chief Executive Officer | $399,970 | $987,630 |
